NASDAQ:MNOV

MediciNova Q1 2026 Earnings Results & Report

MediciNova logo
$1.28 -0.05 (-3.83%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MediciNova beat analyst earnings expectations but missed on revenue in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$0.05 versus the -$0.06 consensus estimate, while revenue of $186.98 thousand fell short of the $187 thousand estimate by $16.00.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
8:00 AM ET

MediciNova EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

MediciNova Revenue Results

Actual Revenue
$186.98 thousand
Expected Revenue
$187 thousand
Beat/Miss
Missed by -$0.02 thousand
YoY Revenue Growth
N/A

Earnings Documents

MediciNova Q1 2026 Earnings FAQ

MediciNova (NASDAQ:MNOV) reported earnings of -$0.05 per share for Q1 2026, beating the consensus estimate of -$0.06. The report was announced on Thursday, May 14, 2026.

MediciNova reported revenue of $186.98 thousand for Q1 2026, against a consensus estimate of $187 thousand.

MediciNova Earnings Headlines

Medicinova Inc
MediciNova to Participate in the Maxim Growth Summit
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
See More MediciNova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email.

About MediciNova

MediciNova (NASDAQ:MNOV) is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries.

Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines.

MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.

View MediciNova Profile